Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Change In Working Capital : HK$0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sichuan Kelun-Biotech Biopharmaceutical Co Change In Working Capital?

Sichuan Kelun-Biotech Biopharmaceutical Co's change in working capital for the quarter that ended in Dec. 2023 was HK$0.0 Mil.

Sichuan Kelun-Biotech Biopharmaceutical Co's change in working capital for the fiscal year that ended in Dec. 2023 was HK$301.4 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Sichuan Kelun-Biotech Biopharmaceutical Co Change In Working Capital Historical Data

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Kelun-Biotech Biopharmaceutical Co Change In Working Capital Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data

Trend

Dec21

Dec22

Dec23

Change In Working Capital

341.73

38.54

301.36

Sichuan Kelun-Biotech Biopharmaceutical Co Quarterly Data
	Sep21	Dec21	Jun22	Sep22	Dec22	Jun23	Dec23
Change In Working Capital	Get a 7-Day Free Trial			-	-	-	-	-

Sichuan Kelun-Biotech Biopharmaceutical Co Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Sichuan Kelun-Biotech Biopharmaceutical Co Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Sichuan Kelun-Biotech Biopharmaceutical Co's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN

Website

http://www.kelun-biotech.com

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is an innovative biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.

Executives

Liu Gexin	2201 Interest of corporation controlled by you
Si Chuan Ke Lun Yao Ye Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Cheng Du Ke Lun Jing Chuan Ke Ji You Xian Gong Si	2201 Interest of corporation controlled by you
Wellington Management Group Llp	2102 Investment manager
Merck & Co., Inc.	2201 Interest of corporation controlled by you
Merck Sharp & Dohme Llc	2101 Beneficial owner
Ke Lun Guo Ji Fa Zhan You Xian Gong Si	2101 Beneficial owner
Li Jun	2201 Interest of corporation controlled by you
Zhou Quan	2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates L.p.	2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates Ltd.	2201 Interest of corporation controlled by you
Idg Breyer Capital Fund L.p.	2201 Interest of corporation controlled by you
Victory Rhythm Limited	2201 Interest of corporation controlled by you
Wealthy Linkage Limited	2101 Beneficial owner
Ho Chi Sing	2201 Interest of corporation controlled by you

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Headlines

No Headlines